Elsevier

Life Sciences

Volume 63, Issue 26, 20 November 1998, Pages 2365-2371
Life Sciences

Interspecies scaling of renally secreted drugs

https://doi.org/10.1016/S0024-3205(98)00525-6Get rights and content

Abstract

The objective of this study is to predict pharmacokinetic parameters (clearance, volume of distribution at steady state, and elimination half-life) in humans from animal data for drugs which are renally secreted in humans. Pharmacokinetic parameters of ten drugs were scaled-up from animal data obtained from the literature. Using simple allometry (pharmacokinetic parameter of interest vs body weight), total, renal and nonrenal clearances, volume of distribution and half-life were predicted in humans. The predicted parameters were compared with the observed parameters. The results of the study indicated that it is likely that the predicted total and renal clearances from animal data will be underestimated in humans for renally secreted drugs. The prediction of renal clearance was improved by normalizing the renal clearance by a ‘correction factor’ for animals who exhibited renal secretion. The predicted volume and half-life were comparable with the observed values in man. Overall, the results of this study indicate that caution should be employed in interpreting the total and renal clearance of renally secreted drugs predicted by the allometric approach.

References (25)

  • I. Mahmood et al.

    J. Pharm. Sci.

    (1996)
  • T. Lave et al.

    J. Pharm. Sci.

    (1995)
  • H. Boxenbaum

    Drug Metab. Rev.

    (1984)
  • H. Boxenbaum et al.

    Eur. J. Drug. Metab and Pharmacokinet.

    (1984)
  • I. Mahmood et al.

    Xenobiotica.

    (1996)
  • K. Bachmann

    J. Appl. Toxicol.

    (1989)
  • I. Mahmood

    J. Pharm. Pharmacol.

    (1998)
  • L. Shargel, A. B. C. Yu. Applied Biopharmaceutics and pharmacokinetics. 3 rd edition. Appleton and Lange. Stamford,...
  • C. Efthymiopoulos et al.

    J. Antimicrob. Chemotherapy.

    (1991)
  • M.G. Jannuzo et al.

    Eur. J. Clin. Pharmacol.

    (1989)
  • B.A. Patel et al.

    J. Pharmacobio-Dyn.

    (1990)
  • S.S. Ibrahim et al.

    J. Pharm. Pharmacol.

    (1989)
  • Cited by (77)

    • Preclinical prediction of human pharmacokinetics

      2021, Atkinson's Principles of Clinical Pharmacology
    • Model-informed drug development and discovery: An overview of current practices

      2020, Remington: The Science and Practice of Pharmacy
    • Human PK Prediction and Modeling

      2017, Comprehensive Medicinal Chemistry III
    • General introduction on pharmaceuticals

      2013, Comprehensive Analytical Chemistry
      Citation Excerpt :

      Although from an environmental perspective, oxidative metabolism appears advantageous in terms of generating products with largely reduced biological activity, synthetic strategies rather aim to reduce the relevance of this pathway. Regardless the balance of phase I and phase II metabolism, or combinations thereof, the extent of direct renal or biliary excretion in humans is difficult to predict based on the outcomes of excretion studies in preclinical species [65,66]. Prior to selecting drug candidates for development, mass balance studies are conducted in animals by collecting urine and feces (or preferably of bile if bile duct ligation is technically feasible) following intravenous bolus administration.

    • Preclinical Prediction of Human Pharmacokinetics

      2012, Principles of Clinical Pharmacology, Third Edition
    View all citing articles on Scopus
    View full text